Review of the key primary outcome data from this trial of subcutaneous daratumumab with bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant eligible multiple myeloma patients.
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Treatment:
This is a video synopsis/summary of a Case-Based Peer Perspectives featuring Douglas Sborov, MD.
The phase 3 PERSEUStrial compared subcutaneous daratumumab plus lenalidomide, bortezomib, and dexamethasone (Dara-RVD) with RVD alone in patients with transplant-eligible newly diagnosed multiple myeloma. Data were first presented at the 2023 American Society of Hematology Annual Meeting and Exposition. The design mirrored the Griffin trial, except for maintenance therapy. The Dara-RVD arm had 2 years of Dara-lenalidomide maintenance, with those patients with minimal residual disease (MRD) positive continuing Dara-lenalidomide and those who were MRD negative continuing lenalidomide alone. Primary end point was progression-free survival (PFS); key secondary end points included response rates, MRD negativity, safety, and overall survival.
PERSEUS solidified quadruplet over triplet therapy in this population based on the significantly improved PFS. As in Griffin, Dara-RVD improved response rates, complete response, and MRD negativity vs RVD consistently across subgroups. Complete response or better rate was 87.9% with Dara-RVD; MRD-negativity rate (10-5 threshold) was 75.2%. At 47.5-month median follow-up, PFS was significantly improved with Dara-RVD (4-year PFS, 84.3%). Whereas Griffin was underpowered for PFS, PERSEUS resolved prior doubts, cementing quadruplet therapy as standard of care for patients with transplant-eligible newly diagnosed multiple myeloma. However, there is debate over the optimal proteasome inhibitor and anti-CD38 antibody in quad regimens.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More